Literature DB >> 17367607

Myometrial dysplasia (atypical myometrial hyperplasia).

Stewart F Cramer1, Patricia M Newcomb, Thomas A Bonfiglio.   

Abstract

Although precursor lesions are well known for cervical and endometrial neoplasms, precursor lesions are not currently recognized for the most common tumor of the uterus-leiomyomas. Myometrial hyperplasia has been recently described and evaluated by morphometry, but its relationship to uterine leiomyomas has not been systematically explored. Myometrial dysplasia (atypical myometrial hyperplasia) has not been previously recognized. We herein report a case of myometrial dysplasia with immunostains for proliferation marker MIB-1 (Ki-67) and for p53. The paradoxical rarity of myometrial dysplasia is considered in comparison to the striking frequency of uterine leiomyomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367607     DOI: 10.1016/j.humpath.2007.01.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  3 in total

1.  Expression of p53 and p21(WAF-1), apoptosis, and proliferation of smooth muscle cells in normal myometrium during the menstrual cycle: implication of DNA damage and repair for leiomyoma development.

Authors:  Ayako Suzuki; Masatoshi Kariya; Noriomi Matsumura; Tsukasa Baba; Haruhiko Yagi; Masaki Mandai; Ikuo Konishi; Shingo Fujii
Journal:  Med Mol Morphol       Date:  2012-12-07       Impact factor: 2.309

2.  Dedifferentiated leiomyosarcoma of the uterus with heterologous elements: a potential diagnostic pitfall.

Authors:  Kojo R Rawish; Oluwole Fadare
Journal:  Case Rep Obstet Gynecol       Date:  2012-10-17

Review 3.  Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction.

Authors:  Andrea Ciavattini; Jacopo Di Giuseppe; Piergiorgio Stortoni; Nina Montik; Stefano R Giannubilo; Pietro Litta; Md Soriful Islam; Andrea L Tranquilli; Fernando M Reis; Pasquapina Ciarmela
Journal:  Obstet Gynecol Int       Date:  2013-09-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.